Publications by authors named "Eileen Elliott"

Claim this Profile
R
RNA-seq characterization of histamine-releasing mast cells as potential therapeutic target of osteoarthritis.
Xiaoyi Zhao, Shady Younis, Hui Shi, Shu Hu, Amin Zia, Eileen E Elliott

Clin Immunol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MicroRNA-mRNA Interactions at Low Levels of Compressive Solid Stress Implicate mir-548 in Increased Glioblastoma Cell Motility.
Mark A Calhoun, Yixiao Cui, Eileen E Elliott, Xiaokui Mo, Jose J Otero

Sci Rep· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dysregulated integrin αVβ3 and CD47 signaling promotes joint inflammation, cartilage breakdown, and progression of osteoarthritis.
Qian Wang, Kazuhiro Onuma, Changhao Liu, Heidi Wong, Michelle S Bloom, Eileen E Elliott

JCI Insight· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond Linear Elastic Modulus: Viscoelastic Models for Brain and Brain Mimetic Hydrogels.
Mark A Calhoun, Sarah A Bentil, Eileen Elliott, Jose J Otero, Jessica O Winter

ACS Biomater Sci Eng· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IgE-mediated mast cell activation promotes inflammation and cartilage destruction in osteoarthritis.
Qian Wang, Christin M Lepus, Harini Raghu, Laurent L Reber, Mindy M Tsai, Eileen E Elliott

Elife· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice.
Ronald P Gladue, Timothy Paradis, Susan H Cole, Carol Donovan, Robin Nelson, Eileen Elliott

Cancer Immunol Immunother· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.
Mark E Flanagan, Todd A Blumenkopf, William H Brissette, Matthew F Brown, Jeffrey M Casavant, Eileen A Elliott

J Med Chem· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates.
Dominic C Borie, Michael J Larson, Mona G Flores, Andrew Campbell, Geraldine Rousvoal, Eileen A Elliott

Transplantation· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates.
Dominic C Borie, Paul S Changelian, Michael J Larson, Ming-Sing Si, Ricardo Paniagua, Eileen A Elliott

Transplantation· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.
Paul S Changelian, Mark E Flanagan, Douglas J Ball, Craig R Kent, Kelly S Magnuson, Eileen A Elliott

Science· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis